Process used to select lung transplant patients may need to be changed: study

November 14, 2017, University of Maryland

With a limited number of lungs available, deciding who gets a transplant can be a matter of life or death. New research from the University of Maryland School of Medicine (UMSOM) suggests that the system for choosing transplant recipients in chronic obstructive pulmonary disease (COPD) may underestimate how long a person might survive without a lung transplant and therefore, may mislead clinicians.

The , introduced in 2004, is widely used to predict how long a person will live with COPD. Known as the BODE score, it combines Body mass index, airflow Obstruction, Dyspnea (shortness of breath) and Exercise capacity.

Researchers who developed the BODE score observed survival for with the most severe disease that was clearly worse than survival after a lung . In time, the BODE score became a quick way to predict survival without transplant and thus to identify those patients suffering from COPD who might live longer with a transplant. "While the BODE score was and remains to be a valuable prognostication tool in COPD, it has not been validated for this particular purpose," says lead investigator Robert M. Reed, MD, UMSOM associate professor of medicine and a pulmonary and critical care specialist at the University of Maryland Medical Center. The originator of the BODE score, Bartolome R. Celli, MD, of the Brigham and Women's Hospital in Boston, is senior author of the current paper.

This study, published online in the journal Chest, compared survival data in the original group of 625 patients (93 percent male) who formed the basis for the BODE score to 4,300 lung transplant patients (49 percent male) who had COPD. Results suggest that the BODE score overestimates mortality risk in lung transplant candidates with COPD. This is likely due to the fact that these patients have a lower burden of other ailments such as cancer and heart disease, and are not active smokers. Patients selected as candidates for survive considerably longer than would be predicted by prognostic estimates extrapolated from the original BODE group.

"Our research shows that we are often transplanting people who may not actually derive a survival advantage at all, and we may be shortening the lives of some people with transplant," says Dr. Reed. COPD accounts for about a third of all lung transplants, but the disease progresses so slowly that patients with very severe COPD can survive without a transplant at levels comparable to those who've had a transplant.

"Statistically, a lung transplant is a risky thing. About half of people are dead 5-6 years after a lung transplant, due to transplant complications, so, obviously, you don't want to transplant people who are likely to live longer if left alone," says Dr. Reed.

The study notes that just as cardiovascular disease and cancer are major killers in the general population, they also play a major role in the deaths of COPD patients. Further, modern lung transplant screening for COPD typically determines that patients with heart disease or cancer, as well as those who have not stopped smoking, are not eligible for transplant.

The paper does not point to a newer, more accurate way to predict transplant survival in COPD patients, but Dr. Reed says the transplant community may want to look at new kinds of measurement. However, he points out that survival is only one factor, albeit a major one, in the very personal decision facing both physician and patient contemplating transplantation.

"Dr. Reed and his team are to be commended for shedding light on some of the issues that attend when the BODE score is used to project the survival of candidates with COPD," says E. Albert Reece, MD, PhD, MBA, vice president for medical affairs at the University of Maryland, the John Z. and Akiko K. Bowers Distinguished Professor and dean of UMSOM. "This study suggests it may be worthwhile to weigh the value of new standards that take into account current transplant center screening practices."

Explore further: Older donor lungs should be considered for transplantation

More information: Robert M. Reed et al, Survival of Lung Transplant Candidates with COPD: BODE Reconsidered, Chest (2017). DOI: 10.1016/j.chest.2017.10.008

Related Stories

Older donor lungs should be considered for transplantation

November 9, 2017
With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published ...

Outcomes of lung transplantations since implementation of need-based allocation system

March 3, 2015
Since implementation of a medical need-based allocation system of donor lungs in 2005, double-lung transplantation has been associated with better graft survival than single-lung transplantation in patients with idiopathic ...

Happy patients, healthy lungs

September 26, 2017
Diseases like chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are hard to treat. Lung transplant is important option for people who do not benefit from other treatments, and understanding the outcomes ...

Statins may help people with COPD live longer

September 8, 2017
(HealthDay)—Drugs known as statins may have benefits beyond lowering "bad" LDL cholesterol levels. A new study suggests people with chronic lung disease who take these drugs may extend their survival.

Shift in lung allocation score alters transplant survival

May 8, 2013
(HealthDay)—An acute increase in lung allocation score (LAS) before transplantation is associated with worse post-transplant survival, according to a study published in the May 7 issue of the Annals of Internal Medicine.

Predicting heart events after liver transplant

July 12, 2017
The first app and score to determine the one-year risk of a liver transplant patient dying or being hospitalized for a heart attack or other cardiovascular complication has been developed by Northwestern Medicine scientists.

Recommended for you

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.